Keyword: Hikma Pharmaceuticals
Hikma thinks it can squeeze some additional juice out of its $2 billion deal for Roxane Laboratories by using a plant it acquired in the deal for contract manufacturing.
For the third year in a row, Express Scripts unveiled a new national formulary excluding dozens of drugs. And for the third year in a row, a short list of winners and losers comprises some of Big Pharma’s biggest launches.
Takeda suffered a defeat in its battle to keep a competitor to its version of an ancient gout drug off the market after a federal court said that Hikma can sell a med with the same active ingredient as Takeda’s Colcrys.